Compass-logo-RGB-outlines.png
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 09, 2022 08:00 ET | Compass Therapeutics
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...